Literature DB >> 10529435

Treating asthma with anti-IgE or anti-IL5.

J Lötvall1, T Pullerits.   

Abstract

In the last decades, several key mechanisms driving asthma pathophysiooogy have been discovered. These include the role of IgE in allergic disease, and the role of IL-5 in eosinophilic inflammation. In the last few years, tools to block each of these have been developed. At this time, early clinical studies with neutralizing antibodies against both IgE and IL-5 have been performed in asthma patients, with promising results, and larger studies are underway. The mechanisms of, and possible role of, both anti-IgE and anti-IL-5 treatment in asthma are discussed in this review article.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529435

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

Review 1.  Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.

Authors:  Aasia Ghazi; Anita Trikha; William J Calhoun
Journal:  Expert Opin Biol Ther       Date:  2011-12-05       Impact factor: 4.388

2.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

3.  Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial.

Authors:  Pamela L Zeitlin; Mila Leong; Jeremy Cole; Raburn M Mallory; Vivian H Shih; Richard F Olsson; Mitchell Goldman
Journal:  J Asthma Allergy       Date:  2018-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.